|
|
Article: Biovest Media Alert: Baltimore Sun Reports on First Patient Worldwide to be Cured of Sickle Cell Disease Using Revimmune Therapy for Bone Marrow Transplant.
- Article from:
- Business Wire
- Article date:
- April 11, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla. -- Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today reported that the Baltimore Sun has published an article written by Stephanie Desmon profiling Revimmune[TM] (high-dose cyclophosphamide) and reports on studies conducted by Johns Hopkins University researchers showing treatment with Revimmune demonstrates remarkable promise for the elimination of transplant rejection, including bone marrow transplant usage to cure chronic illnesses such as sickle cell anemia.
The article reports on the first patient, who was told she had just months to live, but was then cured of sickle ...